肺癌
免疫疗法
医学
抗原
肿瘤科
肺
相(物质)
癌症
癌症研究
免疫学
内科学
化学
有机化学
作者
Fumihiro Ishibashi,Yuichi Sakairi,Takekazu Iwata,Yasumitsu Moriya,Teruaki Mizobuchi,Hidehisa Hoshino,Shigetoshi Yoshida,Hideki Hanaoka,Ichiro Yoshino,Shinichiro Motohashi
标识
DOI:10.1016/j.clim.2020.108457
摘要
We conducted a phase I study of the trans-bronchial injection of α-galactosylceramide (αGalCer)-pulsed antigen presenting cells (APCs) to evaluate their safety, immune responses, and anti-tumor activities. Patients with advanced or recurrent non-small cell lung cancer (NSCLC) refractory to standard treatments were eligible. αGalCer-pulsed APCs were administered intratumorally or intranodally by bronchoscopy. Twenty-one patients were enrolled in this study. No severe adverse events related to the cell therapy were observed during this study in any patient. After αGalCer-pulsed APCs were administrated, increased iNKT cell numbers were observed in PBMCs from eight cases, and IFN-γ producing cells were increased in the peripheral blood of 10 cases. Regarding clinical responses, one case exhibited a partial response and eight were classified as stable disease. In the tumor microenvironment, IFN-γ expression was upregulated after treatment in partial response or stable disease cases and TGF-β was upregulated in progressive disease cases.
科研通智能强力驱动
Strongly Powered by AbleSci AI